Global Choroidal Neovascularization Drug Market Insights, Forecast to 2025
Table of Contents
1 Study Coverage
- 1.1 Choroidal Neovascularization Drug Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Product
- 1.4.2 AVMOC-001
- 1.4.3 BB-3
- 1.4.4 BBT-007
- 1.4.5 DG-3
- 1.4.6 Entolimod
- 1.4.7 EWA-001
- 1.4.8 Others
- 1.5 Market by End User
- 1.5.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by End User
- 1.5.2 Clinic
- 1.5.3 Hospital
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Choroidal Neovascularization Drug Market Size
- 2.1.1 Global Choroidal Neovascularization Drug Revenue 2014-2025
- 2.1.2 Global Choroidal Neovascularization Drug Sales 2014-2025
- 2.2 Choroidal Neovascularization Drug Growth Rate by Regions
- 2.2.1 Global Choroidal Neovascularization Drug Sales by Regions
- 2.2.2 Global Choroidal Neovascularization Drug Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Choroidal Neovascularization Drug Sales by Manufacturers
- 3.1.1 Choroidal Neovascularization Drug Sales by Manufacturers
- 3.1.2 Choroidal Neovascularization Drug Sales Market Share by Manufacturers
- 3.1.3 Global Choroidal Neovascularization Drug Market Concentration Ratio (CR5 and HHI)
- 3.2 Choroidal Neovascularization Drug Revenue by Manufacturers
- 3.2.1 Choroidal Neovascularization Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Choroidal Neovascularization Drug Revenue Share by Manufacturers (2014-2019)
- 3.3 Choroidal Neovascularization Drug Price by Manufacturers
- 3.4 Choroidal Neovascularization Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Choroidal Neovascularization Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Choroidal Neovascularization Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Choroidal Neovascularization Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Choroidal Neovascularization Drug Sales by Product
- 4.2 Global Choroidal Neovascularization Drug Revenue by Product
- 4.3 Choroidal Neovascularization Drug Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Choroidal Neovascularization Drug Breakdown Data by End User
6 North America
- 6.1 North America Choroidal Neovascularization Drug by Countries
- 6.1.1 North America Choroidal Neovascularization Drug Sales by Countries
- 6.1.2 North America Choroidal Neovascularization Drug Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Choroidal Neovascularization Drug by Product
- 6.3 North America Choroidal Neovascularization Drug by End User
7 Europe
- 7.1 Europe Choroidal Neovascularization Drug by Countries
- 7.1.1 Europe Choroidal Neovascularization Drug Sales by Countries
- 7.1.2 Europe Choroidal Neovascularization Drug Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Choroidal Neovascularization Drug by Product
- 7.3 Europe Choroidal Neovascularization Drug by End User
8 Asia Pacific
- 8.1 Asia Pacific Choroidal Neovascularization Drug by Countries
- 8.1.1 Asia Pacific Choroidal Neovascularization Drug Sales by Countries
- 8.1.2 Asia Pacific Choroidal Neovascularization Drug Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Choroidal Neovascularization Drug by Product
- 8.3 Asia Pacific Choroidal Neovascularization Drug by End User
9 Central & South America
- 9.1 Central & South America Choroidal Neovascularization Drug by Countries
- 9.1.1 Central & South America Choroidal Neovascularization Drug Sales by Countries
- 9.1.2 Central & South America Choroidal Neovascularization Drug Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Choroidal Neovascularization Drug by Product
- 9.3 Central & South America Choroidal Neovascularization Drug by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Choroidal Neovascularization Drug by Countries
- 10.1.1 Middle East and Africa Choroidal Neovascularization Drug Sales by Countries
- 10.1.2 Middle East and Africa Choroidal Neovascularization Drug Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Choroidal Neovascularization Drug by Product
- 10.3 Middle East and Africa Choroidal Neovascularization Drug by End User
11 Company Profiles
- 11.1 Cellphire, Inc.
- 11.1.1 Cellphire, Inc. Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Products Offered
- 11.1.5 Cellphire, Inc. Recent Development
- 11.2 Chrysalis BioTherapeutics, Inc.
- 11.2.1 Chrysalis BioTherapeutics, Inc. Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Products Offered
- 11.2.5 Chrysalis BioTherapeutics, Inc. Recent Development
- 11.3 Cleveland BioLabs, Inc.
- 11.3.1 Cleveland BioLabs, Inc. Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Products Offered
- 11.3.5 Cleveland BioLabs, Inc. Recent Development
- 11.4 Cumberland Pharmaceuticals, Inc.
- 11.4.1 Cumberland Pharmaceuticals, Inc. Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Products Offered
- 11.4.5 Cumberland Pharmaceuticals, Inc. Recent Development
- 11.5 Diffusion Pharmaceuticals Inc.
- 11.5.1 Diffusion Pharmaceuticals Inc. Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Products Offered
- 11.5.5 Diffusion Pharmaceuticals Inc. Recent Development
- 11.6 Eli Lilly and Company
- 11.6.1 Eli Lilly and Company Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Products Offered
- 11.6.5 Eli Lilly and Company Recent Development
- 11.7 GNI Group Ltd.
- 11.7.1 GNI Group Ltd. Company Details
- 11.7.2 Company Business Overview
- 11.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Products Offered
- 11.7.5 GNI Group Ltd. Recent Development
- 11.8 Humanetics Corporation
- 11.8.1 Humanetics Corporation Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Humanetics Corporation Choroidal Neovascularization Drug Products Offered
- 11.8.5 Humanetics Corporation Recent Development
- 11.9 INSYS Therapeutics, Inc.
- 11.9.1 INSYS Therapeutics, Inc. Company Details
- 11.9.2 Company Business Overview
- 11.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Products Offered
- 11.9.5 INSYS Therapeutics, Inc. Recent Development
- 11.10 Meabco A/S
- 11.10.1 Meabco A/S Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Meabco A/S Choroidal Neovascularization Drug Products Offered
- 11.10.5 Meabco A/S Recent Development
- 11.11 Neumedicines Inc.
- 11.12 Onconova Therapeutics, Inc.
- 11.13 PharmaIN Corporation
- 11.14 Pluristem Therapeutics Inc.
- 11.15 ProCertus BioPharm Inc.
- 11.16 RDD Pharma Ltd.
- 11.17 RedHill Biopharma Ltd.
- 11.18 RxBio, Inc.
- 11.19 Soligenix, Inc.
12 Future Forecast
- 12.1 Choroidal Neovascularization Drug Market Forecast by Regions
- 12.1.1 Global Choroidal Neovascularization Drug Sales Forecast by Regions 2019-2025
- 12.1.2 Global Choroidal Neovascularization Drug Revenue Forecast by Regions 2019-2025
- 12.2 Choroidal Neovascularization Drug Market Forecast by Product
- 12.2.1 Global Choroidal Neovascularization Drug Sales Forecast by Product 2019-2025
- 12.2.2 Global Choroidal Neovascularization Drug Revenue Forecast by Product 2019-2025
- 12.3 Choroidal Neovascularization Drug Market Forecast by End User
- 12.4 North America Choroidal Neovascularization Drug Forecast
- 12.5 Europe Choroidal Neovascularization Drug Forecast
- 12.6 Asia Pacific Choroidal Neovascularization Drug Forecast
- 12.7 Central & South America Choroidal Neovascularization Drug Forecast
- 12.8 Middle East and Africa Choroidal Neovascularization Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Choroidal Neovascularization Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
The global Choroidal Neovascularization Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Choroidal Neovascularization Drug market based on company, product type, end user and key regions.
This report studies the global market size of Choroidal Neovascularization Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Choroidal Neovascularization Drug in these regions.
This research report categorizes the global Choroidal Neovascularization Drug market by top players/brands, region, type and end user. This report also studies the global Choroidal Neovascularization Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Cellphire, Inc.
Chrysalis BioTherapeutics, Inc.
Cleveland BioLabs, Inc.
Cumberland Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Eli Lilly and Company
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics, Inc.
Meabco A/S
Neumedicines Inc.
Onconova Therapeutics, Inc.
PharmaIN Corporation
Pluristem Therapeutics Inc.
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RxBio, Inc.
Soligenix, Inc.
Market size by Product
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others
Market size by End User
Clinic
Hospital
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Choroidal Neovascularization Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Choroidal Neovascularization Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Choroidal Neovascularization Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Choroidal Neovascularization Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Choroidal Neovascularization Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Choroidal Neovascularization Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.